ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2024
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictors of Multiple Sclerosis After Clinically Isolated Syndrome: A Systematic Review and Meta-Analysis.European journal of neurology · 2026Pooled it
- Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.Neurology and therapy · 2026Review
- The role of age in choosing high-efficacy treatment for multiple sclerosis: an Austrian MS Database study.Journal of neurology · 2026Article
- Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.Therapeutic advances in neurological disorders · 2026Article
- Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.Journal of neurology · 2025Article
- Brain Atrophy and Cognitive Impairment in Primary and Secondary Progressive Multiple Sclerosis Cohort-Similar Progressive MS Phenotype.International journal of molecular sciences · 2025Article
- Advancing multiple sclerosis management in older adults.Nature reviews. Neurology · 2025Article
- Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older Patients.Neurology and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigher age is associated with less inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS). It is unknown whether age itself or disease duration underlies this association.
objectivesThis study investigated the effects of age, disease duration, and inflammatory disease activity in people with RRMS.
methodsIndividual patient-level data from five large phase III randomized controlled trials (RCTs) was utilized to investigate the association of both age and disease duration with annualized relapse rate (ARR), contrast-enhancing lesions (CELs), and new T2 lesions on magnetic resonance imaging (MRI) at baseline and follow-up.
resultsThe data set included 5626 participants. Higher age was associated with lower ARRs, lower CEL number on MRI at baseline and follow-up, and lower new T2 lesion numbers at follow-up. This effect was present in all disease duration groups. For example, we found a lower number of new T2 lesions on MRI during follow-up in higher age groups compared to lower age groups, independent of disease duration.
conclusionAging in RRMS is associated with a lower risk of inflammatory disease activity, across different disease durations. Age should be taken into account when designing clinical trials and future research should investigate how age should be integrated into personalized predictions of treatment response and risk profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.